: Media Relations: Senesco Technologies, Inc. FD FD Bruce Galton Brian Ritchie Irma Gomez-Dib Chief Executive Officer brian.ritchie@fd.com irma.gomez-dib@fd.com bgalton@senesco

Announces H1N1 Influenza Survival Test Results in Mice

BRUNSWICK, N.J. (May 26, 2009) - Senesco Technologies, Inc.

("Senesco" or the "Company") (NYSE Amex: SNT) today reported results of H1N1

mouse influenza survival studies that were conducted in Dr. William Scheld's lab

at the University of Virginia School of Medicine. Mice treated with

an siRNA against Senesco's Factor 5A gene had a 52% survival rate as opposed to

a 14% survival rate for mice that received no treatment or a control

of 73 mice were infected with a lethal dose of nasally administered H1N1 mouse

influenza. The treated mice (n=31 mice) were administered Senesco's

siRNA against Factor 5A approximately 24 hours after infection and then every

other day for 11 days. Treated mice reversed the weight loss

typically seen in infected mice at around day 8 of the study, which coincides

with the reduced mortality. The treated mice had other reduced

indicators of disease severity as measured by blood glucose and liver

Scheld, the Bayer-Gerald L. Mandell Professor of Internal Medicine at the

University of Virginia School of Medicine and past president of the Infectious

Diseases Society of America, commented, "These prototype studies have

demonstrated that Factor 5A is a promising candidate for future study in several

infectious diseases, including a model of lethal influenza."

Galton, Senesco's President and CEO, added, "We believe these data from Dr.

Scheld further underscore Factor 5A's ability to mitigate apoptosis caused by

inflammation, in this case from the H1N1 flu model. As we have

previously stated, one of the attributes of Senesco's Factor 5A technology is

its broad applicability. While we are currently working on our

primary goal of filing an investigational new drug application with the FDA for

the treatment of multiple myeloma, it is important that our other inflammation

programs also progress."

Senesco Technologies, Inc.

Technologies, Inc. is a U.S. biotechnology company, headquartered in New

Brunswick, NJ. Senesco has initiated preclinical research to trigger

or delay cell death in mammals (apoptosis) to determine if the technology is

applicable in human medicine. Accelerating apoptosis may have applications

to development of cancer treatments. Delaying apoptosis may have

applications to certain diseases inflammatory and ischemic diseases.

Senesco takes its name from the scientific term for the aging of plant cells:

senescence. Delaying cell breakdown in plants extends freshness after

harvesting, while increasing crop yields, plant size and resistance to

environmental stress. The Company believes that its technology can be used

to develop superior strains of crops without any modification other than

delaying natural plant senescence. Senesco has partnered with leading-edge

companies engaged in agricultural biotechnology and earns research and

development fees for applying its gene-regulating platform technology to enhance

its partners' products.

statements included in this press release are forward-looking statements within

the meaning of the Private Securities Litigation Reform Act of

1995. Actual results could differ materially from such statements

expressed or implied herein as a result of a variety of factors, including, but

not limited to: the ability of the Company to consummate a financing; the

development of the Company's gene technology; the approval of the Company's

patent applications; the successful implementation of the Company's research and

development programs and joint ventures; the success of the Company's license

agreements; the acceptance by the market of the Company's products; success of

the Company's preliminary studies and preclinical research; competition and the

timing of projects and trends in future operating performance, the Company's

ability to meet its funding milestones under its financing transaction, the

Company's ability to continue to comply with the continued listing standards of

the AMEX, as well as other factors expressed from time to time in the Company's

periodic filings with the Securities and Exchange Commission (the

"SEC"). As a result, this press release should be read in conjunction

with the Company's periodic filings with the SEC. The forward-looking

statements contained herein are made only as of the date of this press release,

and the Company undertakes no obligation to publicly update such forward-looking

statements to reflect subsequent events or circumstances.